top of page
BAYN/BMY: As predicted, Factor XI reduces stroke: will BMY do it too, and what's the opportunity?
As expected, Factor XI heralds a new class for stroke prevention
BAYN/BMY/JNJ: As predicted over 4 years ago in our July 2021 Foveal research Factor XI report, BAYN’s phase III OCENAIC-STROKE trial became the first to demonstrate a reduction in ischemic stroke since the advent of anti-platelets. We continue to remain optimistic for BMY/JNJ Factor XI milvexian phase III LIBREXIA-STROKE in 2026 and see differentiation to BAYN’s asundexian.
bottom of page